Since B-cell type non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) are highly sensitive to lysis by Vγ9Vδ2 T cells in vitro, a pioneering study by Wilhelm and colleagues (58) analyzed in vivo the toxicity, Vγ9Vδ2 T cell activation and anti-lymphoma activity of Pamidronate and IL-2 in 19 patients with NHL or MM. Here, IL2 is linked to lymphoma.